Table 4.

Adverse events reported in ≥5% of participants in any group (safety population)

Adverse EventDaprodustat, n=136, n (%)Darbepoetin Alfa, n=135, n (%)
Nasopharyngitis57 (42)73 (54)
Pharyngitis10 (7)6 (4)
Gastroenteritis7 (5)2 (1)
Shunt stenosis19 (14)20 (15)
Contusion17 (13)11 (8)
Skin abrasion10 (7)7 (5)
Procedural hypotension11 (8)5 (4)
Diarrhea20 (15)12 (9)
Vomiting15 (11)11 (8)
Nausea9 (7)12 (9)
Constipation8 (6)6 (4)
Abdominal discomfort3 (2)7 (5)
Back pain6 (4)10 (7)
Arthralgia5 (4)10 (7)
Muscle spasms7 (5)4 (3)
Pain in extremity1 (<1)10 (7)
Headache8 (6)6 (4)
Pyrexia7 (5)3 (2)
Hypertension5 (4)8 (6)